Products Liability
Depo-Provera, commonly referred to as the “birth control shot,” is a long-acting injectable contraceptive that has been used by millions of women since its approval by the FDA in 1992. Recent scientific research, including a pivotal 2024 British Medical Journal study, has linked Depo-Provera to an increased risk of brain tumors, particularly meningiomas.
Women who have received at least two Depo-Provera injections and later been diagnosed with a brain tumor, such as a meningioma, may qualify to file lawsuits against Pfizer, the drug’s manufacturer. These claims focus on allegations of failure to warn, defective design, and insufficient safety testing of Depo-Provera and its generic equivalents.
Our firm is actively accepting cases from women who meet these criteria. If you or a loved one used Depo-Provera and subsequently developed a brain tumor, call our Depo-Provera attorneys today at Depo-Provera attorneys today at 800-553-8082 or contact us online.
This page will provide updates on the latest developments in the Depo-Provera litigation, including information on brain tumor lawsuits, potential class action filings, and anticipated settlement amounts.
This page will provide updates on the latest developments in the Depo Provera lawsuits as we move towards an MDL in February 2025, as well as our prediction on the potential settlement value of these cases.
Depo-Provera Brain Tumor Lawsuit News and Updates
Legal actions involving Depo-Provera are gaining traction as lawsuits continue to be filed, alleging a connection between the contraceptive and meningioma brain tumors. Plaintiffs across the country are seeking accountability from Pfizer and other manufacturers for failing to provide adequate warnings about these dangers.
This timeline serves as a comprehensive resource for tracking the latest updates in the Depo-Provera litigation. We will provide regular insights into new lawsuits, court rulings, MDL proceedings, and potential settlement developments to keep you informed every step of the way.
June 2, 2025 – MDL Grows
The Depo-Provera MDL is picking up speed fast. As of June 1, 2025, the number of active lawsuits has jumped to 348—up from 289 in May. That is a sharp 20.4% increase in just one month. For a mass tort still taking shape, that kind of growth is significant and we expect to see another jump next month.
May 30, 2025 – Case Management Conference Addresses Litigation Progress
A Case Management Conference was held in the United States Courthouse in Pensacola, Florida, to discuss the status of the Depo-Provera MDL. The court and involved parties reviewed the progress of the litigation and made decisions on how the cases would proceed.
The next conference is scheduled for June 27, 2025.
May 20, 2025 – Court Sets Proof of Use/Injury Requirements
Judge Rodgers issued Pretrial Order #22 requiring each plaintiff to submit a “Proof of Use and Injury Questionnaire” with supporting documentation. The goal is to ensure claims moving forward meet a minimal evidentiary threshold. The order has intensified pressure on law firms to verify that their filed cases are built on solid factual grounds.
May 1, 2025 – Generic Manufacturers Ordered to Participate in Pre-Trial Discovery
Judge Rodgers clarified that generic drug manufacturers Greenstone LLC and Viatris Inc. are expected to remain as defendants and participate fully in pre-trial information sharing and other actions. This decision ensures that plaintiffs who used generic forms of Depo-Provera have a path to pursue justice.
May 18, 2025 – Pfizer Produces Extensive Documentation in Depo-Provera Litigation
Pfizer and its co-defendants have turned over approximately 1 million documents to the courts and plaintiffs’ lawyers, totaling about 8 million pages. This extensive documentation is expected to play a crucial role in litigating preemption and general causation issues in the case.
May 1, 2025 – MDL Grows By Two Cases in April
The Depo-Provera MDL added two new cases this month, increasing the total to 289 from 287. For Pfizer, this calm will not last. A massive wave of filings is coming, and by the end of summer, the case count is expected to more than triple.
Depo Provera – the “Birth Control Shot”
Depo-Provera, formally known as medroxyprogesterone acetate, is a synthetic form of the hormone progesterone and a widely used injectable contraceptive. Developed in the 1960s and approved by the FDA over thirty years ago in 1992, it offers a long-acting birth control method, requiring an injection every three months. This method of contraception has been utilized by millions of women worldwide due to its efficacy and convenience.
The convenience offered by Depo-Provera, requiring just one injection every three months, is attractive to a lot of women. This dosing schedule is particularly advantageous for those who may find daily contraceptive methods challenging to maintain. Its proven effectiveness as a contraceptive method adds to its reliability, making it a trusted choice for women across various regions. In areas where access to daily oral contraceptives is limited or non-existent, Depo-Provera provides an effective alternative, ensuring wider accessibility and helping to meet the family planning needs of a global population.
The contraceptive effectiveness of Depo-Provera is achieved through several mechanisms. Firstly, it suppresses ovulation by maintaining steady hormone levels, preventing the ovaries from releasing eggs. Additionally, it thickens the cervical mucus, creating a robust barrier that sperm cannot easily penetrate, greatly reducing the chances of fertilization. It also modifies the lining of the uterus, making it thinner and less receptive to any fertilized eggs, thereby decreasing the likelihood of implantation.
Common Side Effects of Depo-Provera
Depo-Provera, like all drugs, comes with a range of potential side effects. Some are common and mild, while others may be more serious, especially with long-term use.
1. Changes in Menstrual Cycle
- Irregular bleeding: One of the most common side effects, especially during the first 6 to 12 months of use, is irregular menstrual bleeding. Some women experience spotting, heavy bleeding, or extended periods.
- Amenorrhea: Over time, many women stop having periods altogether, which can be a relief for some but very off-putting for others who worry about getting pregnant in the future.
2. Weight Gain
- Weight gain is a frequently reported side effect. Studies suggest that women may gain 5-10 pounds in the first year of use, with continued weight gain over subsequent years. Why does this happen? Doctors think this is probably due to an increase in appetite and possible changes in metabolism.
3. Mood Changes and Depression
- Some women report mood swings, irritability, and, in rare cases, depression after starting Depo-Provera. If a woman has a history of depression, her healthcare provider may monitor her more closely for mood-related side effects.
4. Headaches
- Headaches and migraines can occur or worsen in some women using Depo-Provera,. These are usually not side-splitting headings for most women.
5. Decreased Libido
- Some users report a reduction in sexual desire, though this varies widely among individuals.
6. Delayed Return to Fertility
- After stopping Depo-Provera, there can be a delay in the return of normal fertility. For some women, it may take up to 10 months or more for ovulation to return and menstruation to normalize.
Bone Density Issues with Depo-Provera
One of the most serious long-term concerns associated with Depo-Provera is its effect on bone mineral density (BMD) and it has been the subject of some litigation, especially in Canada where there is a class action lawsuit. This side effect is especially concerning for younger women, who are in their peak years of bone development. But it is also a worry with older women, especially those at particular risk for osteoporosis.
Why does Depo-Provera cause bone loss? Again, the drug suppresses estrogen production, which is essential for maintaining bone health by slowing bone breakdown and promoting bone regeneration. With lower estrogen levels, women using Depo-Provera experience increased bone loss, particularly in the spine and hips, areas that are most susceptible to fractures.
Research shows that women who use Depo-Provera for two years or more can experience significant reductions in bone mineral density, with the greatest impact on adolescents and young adults. Since these women have not yet reached their peak bone mass, long-term use of Depo-Provera during these crucial years may prevent them from ever achieving maximum bone density, leading to a higher risk of osteoporosis later in life.
Although some recovery of bone density may occur after stopping Depo-Provera, this recovery is often partial and may take several years. The FDA has issued a “black box warning” for Depo-Provera, cautioning that prolonged use can lead to irreversible bone loss.
To mitigate this risk, it is generally recommended that women avoid using Depo-Provera for more than two years unless other contraceptive options are not suitable. Women who use Depo-Provera long-term are advised to ensure adequate intake of calcium and vitamin D, engage in weight-bearing exercise, and undergo regular bone density tests to monitor for signs of bone loss. Women with a family history of osteoporosis or poor nutritional habits may be particularly vulnerable to these effects and should consider alternative contraceptive methods to preserve their bone health.
Research Shows the Depo-Provera Causes Brain Tumors
Now let’s turn to the focus of this new Depo-Provera litigation, the question of whether Depo-Provera causes brain tumors. In 2024, a major scientific study revealed a strong connection between the use of Depo-Provera and the development of a specific type of brain tumor known as meningioma. The study was published in the highly respected British Medical Journal.
The research involved a focus group of over 100,000 women in France between 2009 and 2018. It found that women who used the Depo-Provera birth control shot for an extended period were 5.6 times more likely to develop a meningioma brain tumor.
In the world of statistics, odds ratios, and medical studies, data showing that a drug makes something 5.6 times more likely is overwhelming proof of causation. Studies showing that a disease is 2 or 3 times more likely are considered conclusive evidence and have been the basis of billion dollar product liability settlements in the past.
Meningioma
A meningioma is a tumor that develops from the meninges, the membranes surrounding the brain and spinal cord. While not classified technically as a brain tumor, a meningioma can press on nearby brain tissue, nerves, and blood vessels. It is the most common type of tumor found in the head and it is commonly referred to as a “brain tumor.”
Most meningiomas grow very slowly and may take years to cause noticeable symptoms. However, in some cases, their pressure on nearby brain structures can lead to significant health issues.
Meningiomas are more common in women and are often diagnosed later in life, although they can occur at any age. Due to their slow growth, many meningiomas do not require immediate treatment and can be monitored over time with regular checkups.
Meningiomas are grouped into three separate categories or grades based on certain characteristics. Grade I and Grade II meningiomas are non-cancerous, with Grade II growing faster and being more resistant to treatment. Grade III meningiomas are malignant (cancerous) and very dangerous.
Since most meningiomas are benign (noncancerous), surgery is the most common treatment option. Complete removal of the tumor is preferred to minimize the risk of it returning.
In some cases, radiation therapy may be used to shrink the tumor. It is also an option for targeting small remnants of the tumor left after surgery or for patients who are not well enough to undergo surgery.
Depo-Provera Lawsuit Timeline
January 2025: An MDL hearing at the end of the month will determine where a Depo-Provera MDL will be housed.
December 2024: Plaintiffs’ lawyers file for a Depo-Provera MDL. Pfizer agrees there should be an MDL but disagrees on where it should be located. Plaintiffs seek California; Pfizer prefers New York.
October 2024: Depo-Provera lawsuits intensify as patients allege Pfizer failed to warn them about the risk of intracranial meningiomas.
July 2024: Pfizer updates U.S. prescribing guidelines for Depo-Provera to include brain tumor risks but does not update the official warning label.
March 2024: A major French study links Depo-Provera use for over a year to a 5.6x increased risk of intracranial meningiomas.
2017: Kalamarides et al. publish research showing that discontinuing progestin medications like Depo-Provera can lead to tumor shrinkage.
2015: Cossu et al. conduct a review highlighting the link between progesterone and meningioma growth, showing tumor regression with anti-progesterone agents.
2011: Gil et al. publish a study linking high doses of progestin-based medications like Depo-Provera to elevated meningioma risks.
2004: The FDA approves Depo-SubQ Provera 104, a lower-dose version, though data on long-term neurological safety is limited.
1992: The FDA approves Depo-Provera after decades of opposition due to cancer risks observed in animal studies.
1989: Blankenstein’s study suggests progesterone exposure accelerates meningioma growth, while anti-progesterone agents shrink tumors.
1969: Depo-Provera launches in 90 countries as a contraceptive despite FDA concerns, becoming popular in lower-income communities.
1967: The FDA rejects Upjohn’s first attempt to approve Depo-Provera due to findings of cancerous tumors in animal trials.
1959: Provera, the oral version of medroxyprogesterone acetate, launches as a treatment for irregular menstruation and miscarriage.
Birth Control Shot Lawsuits
Pharmaceutical companies like Pfizer have a legal duty to ensure their products are safe and to provide clear warnings about potential risks. If a manufacturer fails to fulfill this obligation, they can be held responsible for any harm caused by their product.
The connection between Depo-Provera and meningiomas was never included as a potential risk or side effect on its warning label. As a result, Pfizer may be held liable for failing to adequately warn users of this risk.
Who Qualifies to File a Depo-Provera Brain Tumor Lawsuit?
Individuals eligible to file a Depo-Provera lawsuit include women who received at least two injections of the Depo-Provera birth control shot and were later diagnosed with a meningioma or another type of brain tumor. These are the minimum eligibility requirements set by our firm.
Those who used Depo-Provera for longer periods are likely to have stronger claims compared to those who received only a few injections.
Proving a Depo-Provera Brain Tumor Claim
To succeed in a Depo-Provera brain tumor lawsuit, individuals will need to prove two key points: (1) they used the Depo-Provera birth control shot, and (2) they were diagnosed with a meningioma or another type of brain tumor.
While these requirements may seem straightforward, gathering the necessary documentation to support your claim can be a complex process. However, this is not something you need to handle alone—our experienced Depo-Provera attorneys are here to guide you every step of the way.
Evidence of Depo-Provera use can typically be obtained through medical records from the prescribing physician or clinics where you received the injections. Insurance billing records can also provide clear proof of your Depo-Provera usage. For those who may not have easy access to this information, our legal team will work diligently on your behalf to obtain these documents. We have the resources and expertise to navigate medical systems, ensuring the necessary records are collected to support your claim.
Additionally, proof of a brain tumor diagnosis, such as a meningioma, will also require medical documentation. Hospital records, pathology reports, imaging studies like MRIs or CT scans, and treatment records will be essential in establishing this part of your case. Again, you do not need to stress about acquiring these records—our team will handle the heavy lifting. We will coordinate with healthcare providers, hospitals, and diagnostic facilities to compile the evidence needed to strengthen your claim.
Beyond the basic elements of proof, other factors can significantly enhance the strength of your Depo-Provera brain tumor lawsuit. For example, long-term use of Depo-Provera or multiple injections over several years may bolster the argument that the drug contributed to the development of your condition. If you received a higher-dose version of the shot, such as Depo-Provera 150 mg, this can also be an important aspect of your claim, as studies have linked higher doses to an increased risk of meningiomas. Our lawyers are well-versed in identifying and leveraging these factors to build the strongest possible case for you.
Let’s be clear about what eligibility for a Depo Provera lawsuit means. Even if you do not meet these specific criteria, you may still have a valid claim. Every case is unique. And just because you our firm will not take your case does not mean you are not eligible to bring a claim. But we do have set this set criteria.
Is There a Depo Provera Class Action Lawsuit?
As of January 2025, there is not a class action or MDL (multi-district litigation) for the Depo-Provera brain tumor lawsuits. The research linking Depo-Provera to brain tumors was just recently published, however, and it is expected that a growing number of women will file lawsuits over the next few years. Plaintiffs’ Depo shot lawyers have already filed for an MDL and that request will be ruled on very soon.
If a significant volume of these cases get filed in federal courts, we will most likely see the Depo-Provera brain tumor lawsuits consolidated into a class action MDL at some point next year.
What Are Potential Depo-Provera Brain Tumor Lawsuit Settlement Amounts?
First, let’s note that it is important to take any early settlement estimates with a grain of salt, similar to trying to predict the path of a hurricane far in advance. While we can make educated guesses based on past lawsuits with similar injuries, the final outcomes will depend on how the evidence holds up in court and various other unpredictable factors. That said, if the connection between Depo-Provera and meningioma brain tumors can established convincingly to a jury, settlement payouts s could range from $100,000 to $2 million or more. Why such a broad range of possible compensation?
This wide range is largely due to the varying severity of meningiomas. The difference between a Grade I (non-cancerous) meningioma and a malignant Grade III meningioma is significant. A Grade III meningioma is potentially life-threatening and far more serious. Those cases could fetch over $1 million because the potential jury payouts could be in the tens of millions.
Treating a symptomatic intracranial meningioma usually requires highly invasive brain surgery, specifically a craniotomy, where a portion of the skull is removed to access the brain and meninges. Juries will see how awful this is that will translate to Depo Provera settlement amounts when the times comes. There are also risks that involve real pain and suffering even when they do not come to pass.
These are serious surgeries, too. Due to the tumor’s sensitive location, complete removal is often risky and technically challenging, and additional treatments like radiation therapy or chemotherapy may be necessary.
Grade I meningiomas are generally less harmful and rarely life-threatening. But, they may see significant settlements. Because no woman wants to live with the fear of a brain tumor that could get worse, Grade II cases would fall somewhere around the average between the two.
Here’s how potential settlement amounts could break down:
- Grade I meningiomas: These non-cancerous tumors, while less aggressive, still pose health risks and emotional distress. Settlement amounts for Grade I cases might range between $100,000 and $200,000, depending on the specific impact on the plaintiff’s life.
- Grade II meningiomas: These tumors are more serious and come with a higher risk of complications. For plaintiffs with Grade II meningiomas, settlements could range from $200,000 to $800,000. There is a wide range of severity in these Grade II cases.
- Grade III meningiomas: The most severe cases involve malignant, life-threatening tumors. Settlements for Grade III cases could exceed $1 million, and in some instances, may reach $2 million or more, especially where the victim has died or their quality of life has been significantly impacted
These estimates are early projections and may change as more information becomes available during litigation. Just like predicting any uncertain event, actual settlement amounts could vary significantly. We will continue to update these compensation payouts predictions in this space as the litigation unfolds.
Contact Our Depo Provera Lawyers
If you used Depo-Provera and were later diagnosed with a meningioma or another type of brain tumor, reach out to our national product liability attorneys today at 800-553-8082 or connect with us online.